Information Provided By: 
Fly News Breaks for March 4, 2019
DHR
Mar 4, 2019 | 06:47 EDT
JPMorgan analyst Tycho Peterson raised his price target for Danaher to $140 following a closer look at the company's acquisition of GE Biopharma. The deal "bears multiple merits," including a meaningful boost to Danaher's long-term organic growth profile through doubled biopharma exposure, significant opportunities for revenue synergies, and an enhanced competitive positioning, Peterson tells investors in a research note. He reiterates an Overweight rating on Danaher.
News For DHR From the Last 2 Days
